NCAPG2 could be an immunological and prognostic biomarker: From pan-cancer analysis to pancreatic cancer validation

Abstract

More recently, NCAPG2 has emerged as an intrinsically essential participant of the condensin II complex involved in the process of chromosome cohesion and stabilization in mitosis, and its position in particular tumours is now being highlighted. Simultaneously, the genetic properties of NCAPG2 hint that it might have enormous potential to interpret the malignant progression of tumors in a broader perspective, that is, in pan-cancer. Yet, at present, this recognition remains merely superficial and there is a lack of more detailed studies to explore the underlying pathogenesis. To meet this need, the current study was undertaken to comprehensively elucidate the potential functions of NCAPG2 in pan-cancer, based on a combination of existing databases like TCGA and GTEx. NCAPG2 was identified to be overexpressed in almost every tumor and to exhibit significant prognostic and diagnostic efficacy. Furthermore, the correlation between NCAPG2 and selected immune features, namely immune cell infiltration, immune checkpoint genes, TMB, MSI, etc. also indicates that NCAPG2 could potentially be applied in guidance of immunotherapy. Subsequently, in pancreatic cancer, this study further clarified the utility of NCAPG2 that downregulation of its expression could result in reduced proliferation, invasion and metastasis of pancreatic cancer cells, among such phenotypical changes, the epithelial-mesenchymal transition disruption could be at least one of the possible mechanisms raising or enhancing tumorigenesis. Taken above, NCAPG2, as a member of pan-oncogenes, would serve as a biomarker and potential therapeutic target for a range of malignancies, sharing new insights into precision medicine.

Transcriptomics profiling of Parkinson’s disease progression subtypes reveals distinctive patterns of gene expression

“…This gene encodes for a regulatory subunit of the condensin II complex which, along with the condensin I complex, plays a role in chromosome assembly and segregation during mitosis [35]. Alterations of this gene have been associated with cancer and neurodevelopmental defects [36, 37], and although its presence has already been observed in PD blood transcriptomics [38, 39], its role in the disease is still unclear.…”

SLC8A1, a novel prognostic biomarker and immunotherapy target in RSA and UCEC based on scRNA-seq and pan-cancer analysis

“…However, recent research has acknowledged the growing importance of gene in the development of cancer. Wang et al proposed that NCAPG2 could potentially function as a regulatory element and a biomarker for various malignancies [32]. Li et al demonstrated that EIF4G1 may have the ability to modify the tumor microenvironment and inhibit the metastasis of Breast cancer (BRCA), thus potentially serving as a prognostic biomarker and therapeutic target for BRCA [33].…”

Integrative bioinformatics analysis of WDHD1: a potential biomarker for pan-cancer prognosis, diagnosis, and immunotherapy

“…The R package “forest” displayed the results of the prognostic analysis. The Kaplan–Meier (K-M) plots evaluated patient survival status in specific cancers with the R packages “survival” (for statistical analysis) and “survminer” (for visualization) [ 26 , 27 ]. In addition, we assessed the association between WDHD1 expression and patient prognosis using the PrognoScan database ( http://www.prognoscan.org/ ) and independent datasets from the Gene Expression Omnibus (GEO) database ( https://www.ncbi.nlm.nih.gov/geo/ ) [ 28 , 29 ].…”